T-ONE Therapeutics is a pre-clinical biotechnology company pioneering RNA-based medicines that reprogram immune cells to treat cancer and immune-mediated diseases.

The company focuses on LINE1-derived RNAs, non-coding transcripts abundantly expressed in dysfunctional T lymphocytes that accumulate in tumors or during aging.  By modulating these RNAs with antisense oligonucleotides (ASOs), T-ONE aims to awaken and restore immune function.

Building on deep transcriptomic analyses of patient tumors and immune infiltrates, T-ONE is developing first-in-class RNA therapeutics with broad potential across oncology and immunology. Learn more at tonetx.eu

T-ONE THERAPEUTICS

Org chart

Teams

Offices